Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | transient receptor potential cation channel, subfamily V, member 1 | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Wolbachia endosymbiont of Brugia malayi | 2-polyprenyl-6-methoxyphenol 4-hydroxylase | 0.0079 | 0.5 | 0.5 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0079 | 0.5 | 0.5 |
Echinococcus granulosus | protein MICAL 3 | 0.0079 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0079 | 0.5 | 0.5 |
Echinococcus multilocularis | protein MICAL 3 | 0.0079 | 0.5 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0079 | 0.5 | 0.5 |
Trypanosoma brucei | Monooxygenase, putative | 0.0079 | 0.5 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0079 | 0.5 | 0.5 |
Mycobacterium ulcerans | oxidoreductase | 0.0079 | 0.5 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0079 | 0.5 | 0.5 |
Trypanosoma cruzi | Monooxygenase, putative | 0.0079 | 0.5 | 0.5 |
Mycobacterium ulcerans | oxidoreductase GMC-type | 0.0079 | 0.5 | 0.5 |
Toxoplasma gondii | FAD binding domain-containing protein | 0.0079 | 0.5 | 0.5 |
Mycobacterium ulcerans | membrane-associated oxidoreductase | 0.0079 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Possible oxidoreductase | 0.0079 | 0.5 | 0.5 |
Mycobacterium ulcerans | FAD-dependent oxidoreductase | 0.0079 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0079 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0079 | 0.5 | 0.5 |
Plasmodium falciparum | FAD-dependent monooxygenase, putative | 0.0079 | 0.5 | 0.5 |
Trypanosoma brucei | kynurenine 3-monooxygenase, putative | 0.0079 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Possible oxidoreductase | 0.0079 | 0.5 | 0.5 |
Mycobacterium ulcerans | oxidoreductase | 0.0079 | 0.5 | 0.5 |
Toxoplasma gondii | FAD binding domain-containing protein | 0.0079 | 0.5 | 0.5 |
Mycobacterium leprae | possibleputative FAD-linked oxidoreductase | 0.0079 | 0.5 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0079 | 0.5 | 0.5 |
Plasmodium vivax | FAD-dependent monooxygenase, putative | 0.0079 | 0.5 | 0.5 |
Echinococcus multilocularis | ubiquinone biosynthesis monooxygenase COQ6 | 0.0079 | 0.5 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0079 | 0.5 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0079 | 0.5 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.0079 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Possible oxidoreductase | 0.0079 | 0.5 | 0.5 |
Mycobacterium ulcerans | FAD-linked oxidoreductase | 0.0079 | 0.5 | 0.5 |
Echinococcus granulosus | ubiquinone biosynthesis monooxygenase COQ6 | 0.0079 | 0.5 | 0.5 |
Schistosoma mansoni | monoxygenase | 0.0079 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | = -8.7 | Concentration necessary to induce a relative half-maximal response measured by the entry of [Ca2+] into human embryonic kidney HEK-293 cells overexpressing the human VR1 | ChEMBL. | 12166946 |
Log EC50 (functional) | = 8.7 | Concentration necessary to induce a relative half-maximal response measured by the entry of [Ca2+] into human embryonic kidney HEK-293 cells overexpressing the human VR1 | ChEMBL. | 12166946 |
Response (functional) | = 85 % | Percent absolute effect obtained with ionomycin, measured by the entry of [Ca2+] into human embryonic kidney HEK-293 cells overexpressing hVR1 | ChEMBL. | 12166946 |
Response (functional) | = 85 % | Percent absolute effect obtained with ionomycin, measured by the entry of [Ca2+] into human embryonic kidney HEK-293 cells overexpressing hVR1 | ChEMBL. | 12166946 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.